Projects per year
Abstract
Objective: Osteoarthritis causes significant pain and disability with no approved disease-modifying drugs. We systematically reviewed the evidence from both pre-clinical and human studies for the potential disease-modifying effect of metformin in osteoarthritis. Methods: Ovid Medline, Embase and CINAHL were searched between inception and June 2021 using MeSH terms and key words to identify studies examining the association between metformin use and outcome measures related to osteoarthritis. Two reviewers performed the risk of bias assessment and 3 reviewers extracted data independently. Qualitative evidence synthesis was performed. This systematic review is registered on PROSPERO (CRD42021261052 and CRD42021261060). Results: Fifteen (10 pre-clinical and 5 human) studies were included. Most studies (10 pre-clinical and 3 human) assessed the effect of metformin using knee osteoarthritis models. In pre-clinical studies, metformin was assessed for the effect on structural outcomes (n = 10); immunomodulation (n = 5); pain (n = 4); and molecular pathways of its effect in osteoarthritis (n = 7). For human studies, metformin was evaluated for the effect on structural progression (n = 3); pain (n = 1); and immunomodulation (n = 1). Overall, pre-clinical studies consistently showed metformin having a chondroprotective, immunomodulatory and analgesic effect in osteoarthritis, predominantly mediated by adenosine monophosphate-activated protein kinase activation. Evidence from human studies, although limited, was consistent with findings in pre-clinical studies. Conclusion: We found consistent evidence across pre-clinical and human studies to support a favourable effect of metformin on chondroprotection, immunomodulation and pain reduction in knee osteoarthritis. Further high-quality clinical trials are needed to confirm these findings as metformin could be a novel therapeutic drug for the treatment of osteoarthritis.
| Original language | English |
|---|---|
| Pages (from-to) | 1434-1442 |
| Number of pages | 9 |
| Journal | Osteoarthritis and Cartilage |
| Volume | 30 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - 1 Nov 2022 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Disease-modifying
- Human
- Metformin
- Osteoarthritis
- Pre-clinical
- Systematic review
-
Optimizing the management of osteoarthritis through research and innovation
Cicuttini, F. (Primary Chief Investigator (PCI))
1/01/21 → 31/12/26
Project: Research
-
HeLP-knee (Healthy Lifestyle Program for people with knee pain) – a sustainable low-intensity self-management lifestyle intervention for reducing the burden of knee pain in the community
Wang, Y. (Primary Chief Investigator (PCI))
1/01/19 → 31/12/22
Project: Other
-
Improving outcomes in low back pain: understanding the risk factors and patient subgroups
Hussain, M. (Primary Chief Investigator (PCI)) & Cicuttini, F. (Supervisor)
1/01/18 → 30/04/23
Project: Research
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver